RVNC - Revance Therapeutics Inc. (RVNC) Q1 2024 Earnings Call Transcript
2024-05-09 22:42:09 ET
Revance Therapeutics Inc. (RVNC)
Q1 2024 Results Earnings Conference Call
May 9, 2024, 04:30 PM ET
Company Participants
Laurence Watts - Investor Relations, New Street IR
Mark Foley - Chief Executive Officer
Tobin Schilke - Chief Financial Officer
Conference Call Participants
Seamus Fernandez - Guggenheim Partners
Stacy Ku - TD Cowen
Annabel Samimy - Stifel Financial
Chris Shibutani - Goldman Sachs
David Amsellem - Piper Sandler
Daniel Ziment - Morgan Stanley
Serge Belanger - Needham & Co.
Lachlan Hanbury-Brown - William Blair
Navann Ty - Exane BNP Paribas
Presentation
Operator
Welcome to the Revance Therapeutics First Quarter2024 Financial Results and Corporate Update Conference Call. At this time, all participants are in a listen-only mode. [Operator Instructions]. As a reminder, this call is being recorded today, Thursday, May 9, 2024.
I would now like to turn the conference call over to Laurence Watts of New Street Investor Relations. Please go ahead.
Laurence Watts
Thank you, operator. Joining us on the call today from Revance are President and Chief Executive Officer, Mark Foley, and Chief Financial Officer, Toby Schilke.
During this call, management will make forward-looking statements, including statements related to the impact of our pricing and strategy on DAXXIFY on adoption; expectations related to product adoption, account activation and reorders; consumer needs, preferences, and behavior; the benefits and value to us, practices, and consumers of our product, including the efficacy, duration, skin quality, and safety of our products; access to our products; future therapeutic indications; 2024 guidance; cash flow breakeven; positive adjusted EBITDA; future capital expenditures; anticipated revenue and top line growth; our strategic priorities; our anticipated success; our blockbuster potential; our ability to grow and take share; our market opportunity and expectations; our strategy, planned operations, and commercialization plans, including consumer offers and timing of those plans.
Our actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties. Factors that could cause these results to be different from these statements, include factors the company describes in the section called Risk Factors in our in our annual report on Form 10-K and our quarterly report on Form 10-Q. Revance undertakes no duty or obligation to update any forward-looking statements as a result of new information, future events or changes in its expectations.
Also on today's call, we will present both GAAP and non-GAAP financial measures. Reconciliations of GAAP to non-GAAP measures are included in our earnings release.
With that, I will turn the call over to Mark Foley, President and Chief Executive Officer of Revance. Mark?...
Revance Therapeutics Inc. (RVNC) Q1 2024 Earnings Call Transcript